Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.17
PMD's Cash-to-Debt is ranked lower than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. PMD: 1.17 )
Ranked among companies with meaningful Cash-to-Debt only.
PMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: No Debt Max: No Debt
Current: 1.17
Equity-to-Asset 0.62
PMD's Equity-to-Asset is ranked higher than
59% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PMD: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
PMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.8 Max: 0.89
Current: 0.62
0.53
0.89
Interest Coverage 97.21
PMD's Interest Coverage is ranked higher than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. PMD: 97.21 )
Ranked among companies with meaningful Interest Coverage only.
PMD' s Interest Coverage Range Over the Past 10 Years
Min: 97.21  Med: No Debt Max: No Debt
Current: 97.21
Piotroski F-Score: 8
Altman Z-Score: 9.54
Beneish M-Score: -2.43
WACC vs ROIC
9.20%
44.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 25.94
PMD's Operating Margin % is ranked higher than
92% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. PMD: 25.94 )
Ranked among companies with meaningful Operating Margin % only.
PMD' s Operating Margin % Range Over the Past 10 Years
Min: 5.45  Med: 20.88 Max: 29.06
Current: 25.94
5.45
29.06
Net Margin % 17.13
PMD's Net Margin % is ranked higher than
92% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. PMD: 17.13 )
Ranked among companies with meaningful Net Margin % only.
PMD' s Net Margin % Range Over the Past 10 Years
Min: 5.6  Med: 12.97 Max: 18.25
Current: 17.13
5.6
18.25
ROE % 52.14
PMD's ROE % is ranked higher than
98% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. PMD: 52.14 )
Ranked among companies with meaningful ROE % only.
PMD' s ROE % Range Over the Past 10 Years
Min: 12.33  Med: 27.12 Max: 52.14
Current: 52.14
12.33
52.14
ROA % 28.09
PMD's ROA % is ranked higher than
97% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. PMD: 28.09 )
Ranked among companies with meaningful ROA % only.
PMD' s ROA % Range Over the Past 10 Years
Min: 6.55  Med: 22.36 Max: 31.12
Current: 28.09
6.55
31.12
ROC (Joel Greenblatt) % 59.17
PMD's ROC (Joel Greenblatt) % is ranked higher than
82% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. PMD: 59.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.62  Med: 72.02 Max: 202.99
Current: 59.17
8.62
202.99
3-Year Revenue Growth Rate 12.10
PMD's 3-Year Revenue Growth Rate is ranked higher than
74% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. PMD: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10  Med: 5.7 Max: 13.7
Current: 12.1
-10
13.7
3-Year EBITDA Growth Rate 22.30
PMD's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. PMD: 22.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.9  Med: 1.6 Max: 47.1
Current: 22.3
-27.9
47.1
3-Year EPS without NRI Growth Rate 19.20
PMD's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. PMD: 19.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55  Med: -3.6 Max: 138.1
Current: 19.2
-55
138.1
» PMD's 10-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PMD Guru Trades in Q1 2016

Chuck Royce 37,500 sh (unchged)
Jim Simons 410,400 sh (-5.85%)
» More
Q2 2016

PMD Guru Trades in Q2 2016

Chuck Royce 37,500 sh (unchged)
Jim Simons 407,100 sh (-0.80%)
» More
Q3 2016

PMD Guru Trades in Q3 2016

Jim Simons 434,700 sh (+6.78%)
Chuck Royce 37,500 sh (unchged)
» More
Q4 2016

PMD Guru Trades in Q4 2016

Jim Simons 499,990 sh (+15.02%)
Chuck Royce 37,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:BASI, NYSE:BIO » details
Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Psychemedics Corp is a Delaware corporation organized on September 24, 1986. The Company is a provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company's tests provide quantitative information that can indicate the approximate amount of drug ingested as well as historical data, which can show a pattern of individual drug use over a longer period of time, thereby providing superior detection compared to other types of drug testing. This information is useful to employers for both applicant and employee testing, as well as to physicians, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The Company markets its corporate drug testing services through its own sales force and through distributors. Sales offices are located in cities in the United States in order to facilitate communications with corporate employers. The Company markets its home drug testing service, PDT-90, through the Internet. The Company's customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and internationally. The Company competes directly with commercial laboratories that test for drugs mainly through urinalysis testing. The Company is licensed as a clinical laboratory by the State of California as well as certain other states.

Top Ranked Articles about Psychemedics Corp

Psychemedics Corp. on Cusp of Significant Revenue Growth A long-awaited Brazil expansion finally appears to be gaining traction
Psychemedics Corp. (NASDAQ:PMD) is going to enjoy spectacular earnings growth in 2016 if (now mandatory) hair tests for truck drivers are implemented. Brazil is plagued by a high accident rate involving truck drivers, possibly because some engage in drug use (amphetamines to stay awake during long-distance hauls) and/or abuse alcohol. Government has passed a law that requires truck drivers to pass a hair drug test every five years to keep their license. Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.58
PMD's PE Ratio is ranked higher than
83% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. PMD: 15.58 )
Ranked among companies with meaningful PE Ratio only.
PMD' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 20.29 Max: 64.78
Current: 15.58
9.07
64.78
PE Ratio without NRI 15.58
PMD's PE Ratio without NRI is ranked higher than
81% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. PMD: 15.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
PMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 20.29 Max: 64.78
Current: 15.58
9.07
64.78
Price-to-Owner-Earnings 19.03
PMD's Price-to-Owner-Earnings is ranked higher than
76% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. PMD: 19.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.5  Med: 22.76 Max: 185.89
Current: 19.03
7.5
185.89
PB Ratio 6.66
PMD's PB Ratio is ranked lower than
75% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. PMD: 6.66 )
Ranked among companies with meaningful PB Ratio only.
PMD' s PB Ratio Range Over the Past 10 Years
Min: 1.98  Med: 5.79 Max: 9.98
Current: 6.66
1.98
9.98
PS Ratio 2.66
PMD's PS Ratio is ranked higher than
59% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. PMD: 2.66 )
Ranked among companies with meaningful PS Ratio only.
PMD' s PS Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.6 Max: 4.48
Current: 2.66
0.92
4.48
Price-to-Free-Cash-Flow 14.55
PMD's Price-to-Free-Cash-Flow is ranked higher than
73% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. PMD: 14.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.67  Med: 19.87 Max: 86.36
Current: 14.55
6.67
86.36
Price-to-Operating-Cash-Flow 11.25
PMD's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. PMD: 11.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.95  Med: 15.93 Max: 28.12
Current: 11.25
5.95
28.12
EV-to-EBIT 10.19
PMD's EV-to-EBIT is ranked higher than
86% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. PMD: 10.19 )
Ranked among companies with meaningful EV-to-EBIT only.
PMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 11.9 Max: 82
Current: 10.19
4.1
82
EV-to-EBITDA 8.33
PMD's EV-to-EBITDA is ranked higher than
83% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. PMD: 8.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
PMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 10.95 Max: 28.4
Current: 8.33
3.7
28.4
PEG Ratio 3.83
PMD's PEG Ratio is ranked lower than
64% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. PMD: 3.83 )
Ranked among companies with meaningful PEG Ratio only.
PMD' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.16 Max: 137.61
Current: 3.83
0.47
137.61
Shiller PE Ratio 28.42
PMD's Shiller PE Ratio is ranked higher than
67% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. PMD: 28.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
PMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.64  Med: 17.99 Max: 39.49
Current: 28.42
6.64
39.49
Current Ratio 2.41
PMD's Current Ratio is ranked higher than
52% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. PMD: 2.41 )
Ranked among companies with meaningful Current Ratio only.
PMD' s Current Ratio Range Over the Past 10 Years
Min: 2.28  Med: 4.54 Max: 8.59
Current: 2.41
2.28
8.59
Quick Ratio 2.41
PMD's Quick Ratio is ranked higher than
58% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. PMD: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
PMD' s Quick Ratio Range Over the Past 10 Years
Min: 2.28  Med: 4.52 Max: 8.59
Current: 2.41
2.28
8.59
Days Sales Outstanding 54.66
PMD's Days Sales Outstanding is ranked higher than
59% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. PMD: 54.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
PMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.89  Med: 57.01 Max: 70.9
Current: 54.66
47.89
70.9
Days Payable 28.38
PMD's Days Payable is ranked lower than
80% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. PMD: 28.38 )
Ranked among companies with meaningful Days Payable only.
PMD' s Days Payable Range Over the Past 10 Years
Min: 8.99  Med: 22.11 Max: 36.51
Current: 28.38
8.99
36.51

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.15
PMD's Dividend Yield % is ranked higher than
82% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.82 vs. PMD: 3.15 )
Ranked among companies with meaningful Dividend Yield % only.
PMD' s Dividend Yield % Range Over the Past 10 Years
Min: 2.11  Med: 4.58 Max: 18.28
Current: 3.15
2.11
18.28
Dividend Payout Ratio 0.49
PMD's Dividend Payout Ratio is ranked lower than
80% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. PMD: 0.49 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PMD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.98 Max: 2.14
Current: 0.49
0.49
2.14
Forward Dividend Yield % 3.15
PMD's Forward Dividend Yield % is ranked higher than
79% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.16 vs. PMD: 3.15 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.68
PMD's 5-Year Yield-on-Cost % is ranked higher than
79% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. PMD: 3.68 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PMD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.47  Med: 5.36 Max: 21.4
Current: 3.68
2.47
21.4
3-Year Average Share Buyback Ratio -0.90
PMD's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. PMD: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.9  Med: -0.2 Max: 1.9
Current: -0.9
-0.9
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 73.12
PMD's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.90 vs. PMD: 73.12 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.53  Med: 10.17 Max: 94.92
Current: 73.12
3.53
94.92
Price-to-Tangible-Book 6.65
PMD's Price-to-Tangible-Book is ranked lower than
61% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. PMD: 6.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 7.38 Max: 12.74
Current: 6.65
3.19
12.74
Price-to-Intrinsic-Value-Projected-FCF 2.85
PMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
59% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. PMD: 2.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 2.12 Max: 4.93
Current: 2.85
0.69
4.93
Price-to-Median-PS-Value 1.03
PMD's Price-to-Median-PS-Value is ranked higher than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. PMD: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.23 Max: 3.21
Current: 1.03
0.57
3.21
Price-to-Graham-Number 2.15
PMD's Price-to-Graham-Number is ranked higher than
68% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. PMD: 2.15 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.78 Max: 15.19
Current: 2.15
1.27
15.19
Earnings Yield (Greenblatt) % 9.79
PMD's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. PMD: 9.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 8.4 Max: 24.3
Current: 9.79
1.2
24.3
Forward Rate of Return (Yacktman) % 0.28
PMD's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. PMD: 0.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.6  Med: 7.3 Max: 40.8
Current: 0.28
-9.6
40.8

More Statistics

Revenue (TTM) (Mil) $38.98
EPS (TTM) $ 1.22
Beta0.96
Short Percentage of Float0.47%
52-Week Range $10.81 - 27.46
Shares Outstanding (Mil)5.46
» More Articles for PMD

Headlines

Articles On GuruFocus.com
Psychemedics Remains Undervalued Even After Run-up Aug 22 2016 
Psychemedics Corp. on Cusp of Significant Revenue Growth Apr 17 2016 
Psychemedics: World’s Largest Provider of Hair Testing for Drug Abuse Dec 14 2012 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
7 Highly Profitable Healthcare Dividend Stocks with Great Yields Mar 02 2012 
Guru Stocks Raising Dividends: EPR, CB, PMD, BLK, WSBC Feb 27 2012 
Psychemedics Corp: Value in Hair Analysis (PMD) Mar 23 2011 
Psychemedics Corp Reports Operating Results (10-Q) Nov 12 2010 
Psychemedics Corp Reports Operating Results (10-Q) Aug 13 2010 

More From Other Websites
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Psychemedics Corporation Of Imminent... Mar 26 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 24 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 24 2017
Psychemedics Corp. :PMD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 22 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to... Mar 21 2017
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 20 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to... Mar 17 2017
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 16 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Mar 15 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 15 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 14 2017
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class... Mar 13 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to... Mar 13 2017
PSYCHEMEDICS CORP Financials Mar 11 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Psychemedics... Mar 09 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)